Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum
NCT ID: NCT03540498
Last Updated: 2019-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2016-10-13
2017-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study is to assess whether the daily consumption of AB-DENTALAC gum allows the colonization of strains L.plantarum KABP051 (CECT7481) and L.brevis KABP052 (CECT7480) in the oral microbiota, and to confirm the absence of side effects, with the following setup:
1. Number of patients to be randomized:40
2. Number of visits per patient: 2
The study will determine the index of plaque and gingival index as a measure of oral health. The presence of Lactobacillus in the samples collected by qPCR will also be quantified.
The patient will benefit from a buccal revision and control by a periodontist for 6 weeks. It will also help subsequent patients to obtain a better treatment (if the results are significant). No harm is expected to participate, it is a minimal risk study, with non-invasive exploratory tests and a product suitable for human consumption and marketed in Europe since 2012.
The potential patients to participate in the study will be healthy patients, so if they do not wish to participate they will not need alternative treatment. The objective of the study is to see if the probiotic is able to colonize the mouth in healthy patients, it is not a study to demonstrate the effectiveness of the product.
If there is any serious adverse effect (something totally unexpected being a product with probiotic strains QPS), the patient will be advised to stop taking the product immediately. It is not anticipated that the use of any additional treatment is necessary.
The promoter will provide all the necessary material for the study: 60 cases of placebo chewing gum, 60 cases of probiotic chewing gum, and cleaning material (toothbrush and fluoridated toothpaste) for all patients.
Statistical analysis of bacterial colonization will be performed using Student's T with logarithmic transformation of data if required, considering a two-tailed P \<0.05 as significance cut-off.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
The randomization will be made from an online software available at www.randomization.com. From the list of randomization generated by this software, the different products will be labeled with the patient number and the test code. The team of researchers will not have access to the randomization list. In this way, a correct randomization and double-blind trial is guaranteed.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotics
The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS\_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
AB-DENTALAC [Probiotics (study)]
Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
Control
The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
Placebo (control)
Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AB-DENTALAC [Probiotics (study)]
Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
Placebo (control)
Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capacity to understand the procedures and implications of the study.
* Gingival Index \<1,5 (Löe and Silness, Acta Odontol Scand. 1963. 21:533-51)
* Plaque Index \<2,0 (Löe and Silness, Acta Odontol Scand. 1963. 21:533-51)
* Periodontal pocket depth \<5 mm
Exclusion Criteria
* More than 2 untreated caries at the time of enrollment
* Current orthodontic or periodontal treatment
* Hypersensitivity or allergy to any of the ingredients of the experimental product
* Consumption of antibiotics in the 8 weeks prior to treatment
* Use of probiotics designed to improve oral health, or having consumed them during the 8 weeks prior to the study
* Consumption of any type of probiotic during the 4 weeks prior to the study
* Usual consumption of clorhexidine or other mouthwashes with bactericidal active ingredients during the 30 days before the start of the study
* Pregnant or lactating women
* Participants with chronic diseases (eg, diabetes, kidney problems, cancer) or under chronic treatment
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clínica Odontológica Nart en Barcelona
UNKNOWN
AB Biotics, SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jordi Espadaler Mazo, PhD
Role: STUDY_CHAIR
AB Biotics, SA
Jose Nart Molina, DMD
Role: PRINCIPAL_INVESTIGATOR
Clínica Odontológica Nart en Barcelona
References
Explore related publications, articles, or registry entries linked to this study.
Nart J, Jimenez-Garrido S, Ramirez-Sebastia A, Asto E, Buj D, Huedo P, Espadaler J. Oral colonization by Levilactobacillus brevis KABPTM-052 and Lactiplantibacillus plantarum KABPTM-051: A Randomized, Double-Blinded, Placebo-Controlled Trial (Pilot Study). J Clin Exp Dent. 2021 May 1;13(5):e433-e439. doi: 10.4317/jced.57771. eCollection 2021 May.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AB-GUM-2016
Identifier Type: -
Identifier Source: org_study_id